Cuprina Holdings (Cayman) Limited

Cuprina Holdings (Cayman) Limited

NNASDAQ:CUPR
1.68
USD
-0.01
(-0.59%)
8.58MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.02
0.02
0.04
0.02
0.02
- -
Basic EPS, GAAP
-0.2
-0.42
-0.41
-0.57
-1.74
- -
Free Cash Flow per Basic Share
-0.09
-0.71
-0.35
-0.46
-3.43
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.25
-0.65
-1.07
-1.64
1.89
1.89
Tangible Book Value per Share
-0.25
-0.65
-1.07
-1.64
1.89
1.89
Basic Weighted Avg Shares
3
3
3
3
3
3
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-885.52
-1,987.17
-1,021.84
-3,061.7
-9,154.62
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-1
-1
-2
-5
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-888.29
-1,933.81
-1,110.97
-3,229.52
-9,366.75
- -
Working Capital
-1
-2
-3
-4
4
4
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
-1
-2
-3
-4
5
5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

SGD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
- -
160
11

Working Capital

SGD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2
11
7
Cash, Cash Equivalents & STI
- -
4
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
3
3
Payables & Accruals
6
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SGD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-213.36%
Free Cash Flow
- -
- -
630.78%
Net Income, GAAP
- -
- -
199.48%
Sales/Revenue/Turnover
- -
- -
3.26%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

SGD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

SGD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.41
2024
- -
- -
-0.57
2025
- -
- -
-1.74

Semi-annual Dividends Per Share

SGD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

CEO
Yong Qi Quek
Full Time Employees
10
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Blk 1090 Lower Delta Road #06-08 Singapore CE Singapore 169201
IPO Date
Apr 10, 2025
Business
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, develops and commercializes innovative products for chronic wound management and operates in the health and beauty sectors; its core offerings include medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand for maggot debridement therapy, which non-surgically removes necrotic, sloughy or infected tissue from chronic wounds such as diabetic foot ulcers, venous leg ulcers and pressure ulcers; collagen wound care dressings comprising sponges, particles and hydrogels derived from bullfrog collagen sourced from abattoir waste; MEND Skin Restoration Balm, a hydrating product developed with Full Crimp Milk LLP for sports enthusiasts; Activ Labs range of energy and relief products targeted at athletes; and pipeline products utilizing medical leeches for wound treatment. The company serves healthcare providers and patients globally, with operations focused on Asia including Singapore and Hong Kong, and expansion into the US, GCC region and Southeast Asia; it targets markets for chronic wounds affecting millions, such as over 10.5 million Medicare beneficiaries in the US. Founded in 2019 and headquartered in Singapore, Cuprina Holdings (Cayman) Limited functions as a subsidiary of Cuprina Holding Pte. Ltd.. Recent developments include its initial public offering in 2025, which raised gross proceeds of $13.8 million through the sale of Class A ordinary shares on Nasdaq under the ticker CUPR, providing capital for R&D, market expansion, infrastructure upgrades and working capital; formation of a joint venture with Aiodine Laboratory Pte Ltd in November 2025 to develop, test and commercialize a novel iodine-based disinfectant solution for antiseptic wound care, disinfectants, home-use antiseptics and potential applications in personal care, oral hygiene and veterinary uses, with Cuprina responsible for global sales, marketing and distribution and clinical studies planned for 2026; appointment of Dr. Ronald A. Sherman, a pioneer in medical maggot therapy, as Medical and Scientific Director in September 2025, along with securing a license for his 2004 FDA clearance of Lucilia sericata Medical Maggots in the US; signing of a memorandum of understanding with Singapore Biowaste Solutions in October 2025 to integrate medical maggot therapy with biowaste solutions; and securing exclusive rights to a medical waste recycling technology for Southeast Asia in September 2025.

Company News

  • Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group

  • Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter's Over-Allotment Option in Connection with Public Offering

  • Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Shares Shorted: Short Interest Up 223.6% in September

  • Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering

  • Super Copper Featured at OTC Markets' Virtual Investor Conference, Presentation Replay Now Available

  • Cuprina Holdings Falls 22% After 112% Rally — Here's Why CUPR Stock Is Trending

  • Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product

  • Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements

  • Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing

  • Cuprina Holdings announces 1-for-8 Share Consolidation

  • CUPR Investors Have Opportunity to Join Cuprina Holdings (Cayman) Limited Fraud Investigation with the Schall Law Firm

  • CUPR Investors Have Opportunity to Join Cuprina Holdings (Cayman) Limited Fraud Investigation with the Schall Law Firm

  • Rosen Law Firm Encourages Cuprina Holdings (Cayman) Ltd. Investors to Inquire About Securities Class Action Investigation – CUPR

  • Rosen Law Firm Encourages Cuprina Holdings (Cayman) Ltd. Investors to Inquire About Securities Class Action Investigation – CUPR

  • Super Copper Announces Investor Relations Agreement

  • Cuprina Holdings (Cayman) (NASDAQ:CUPR) Shares Down 2.4% – Should You Sell?

  • Financial Review: Petros Pharmaceuticals (NASDAQ:PTPI) & Cuprina Holdings (Cayman) (NASDAQ:CUPR)

  • Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board

  • Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

  • Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies